Unresectable Stage IIIB-IV Malignant Melanoma
Showing 1 - 25 of >10,000
Unresectable Stage IIIB-IV Malignant Melanoma Trial in Japan (Talimogene laherparepvec)
Completed
- Unresectable Stage IIIB-IV Malignant Melanoma
- Talimogene laherparepvec
-
Nagoya-shi, Aichi, Japan
- +8 more
Jan 13, 2023
Metastatic Malignant Tumor in the Brain, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7 Trial in Houston (drug,
Active, not recruiting
- Metastatic Malignant Neoplasm in the Brain
- +7 more
- Binimetinib
- +6 more
-
Houston, TexasM D Anderson Cancer Center
Jun 15, 2022
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Bladder Carcinoma
Recruiting
- Clinical Stage III Cutaneous Melanoma AJCC v8
- +41 more
- Ipilimumab
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Oct 11, 2022
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8
Recruiting
- Anatomic Stage III Breast Cancer AJCC v8
- +129 more
- Cyclophosphamide
- +3 more
-
Jacksonville, FloridaMayo Clinic in Florida
Apr 8, 2022
BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Malignant Solid Tumor Trial in Boston (Dabrafenib,
Active, not recruiting
- BRAF V600E Mutation Present
- +9 more
- Dabrafenib
- +4 more
-
Boston, Massachusetts
- +1 more
Jun 28, 2022
AIDS-Related Non-Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8 Trial in United
Recruiting
- AIDS-Related Non-Hodgkin Lymphoma
- +29 more
- Laboratory Biomarker Analysis
- Pembrolizumab
-
Birmingham, Alabama
- +12 more
Aug 4, 2022
Advanced Malignant Solid Tumor, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Recruiting
- Advanced Malignant Solid Neoplasm
- +28 more
- Capecitabine
- +16 more
-
Conroe, Texas
- +4 more
Dec 5, 2022
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal
Recruiting
- Clinical Stage III Cutaneous Melanoma AJCC v8
- +38 more
- Pembrolizumab
- Sonidegib
-
Scottsdale, Arizona
- +2 more
Aug 27, 2021
Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hodgkin Lymphoma Trial in
Active, not recruiting
- Metastatic Melanoma
- +22 more
- Ipilimumab
- +3 more
-
Birmingham, Alabama
- +24 more
Jan 19, 2023
Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7 Trial in Rochester (drug,
Active, not recruiting
- Metastatic Melanoma
- +6 more
- Ibrutinib
- +2 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 13, 2023
Metastatic Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7 Trial in Jacksonville (drug,
Active, not recruiting
- Metastatic Melanoma
- +3 more
- Imiquimod
- +2 more
-
Jacksonville, FloridaMayo Clinic in Florida
Jan 3, 2023
Clinical Stage III Cutaneous Melanoma AJCC v8, Stage IV Melanoma, Unresectable Stage III Cutaneous Melanoma Trial in Boston
Recruiting
- Clinical Stage III Cutaneous Melanoma AJCC v8
- +3 more
-
Boston, Massachusetts
- +2 more
Sep 17, 2022
Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7 Trial in
Active, not recruiting
- Stage III Cutaneous Melanoma AJCC v7
- +4 more
- Cryosurgery
- +3 more
-
Rochester, MinnesotaMayo Clinic
Jan 3, 2023
Melanoma Stage III, Melanoma Stage IV Trial in San Francisco (Binimetinib, Imatinib)
Recruiting
- Melanoma Stage III
- Melanoma Stage IV
-
San Francisco, CaliforniaUniversity of California, San Francisco
Dec 6, 2022
Melanoma Trial in Wollstonecraft, Cairns (tigilanol tiglate)
Recruiting
- Melanoma
- tigilanol tiglate
-
Wollstonecraft, New South Wales, Australia
- +2 more
Oct 6, 2022
Stage III Malignant Melanoma of Skin AJCC V6, Stage IV Malignant Melanoma of Skin Trial in Santiago (TAPCells vaccine)
Completed
- Stage III Malignant Melanoma of Skin AJCC V6
- Stage IV Malignant Melanoma of Skin
- TAPCells vaccine
-
Santiago, RM, ChileFaculty of Medicine, University of Chile
Nov 21, 2023
Unresectable Melanoma, Metastatic Melanoma, Stage III NSCLC Trial in Louisville, New York (IOV-4001)
Recruiting
- Unresectable Melanoma
- +3 more
- IOV-4001
-
Louisville, Kentucky
- +2 more
Nov 21, 2022
China With Non-Small-Cell Lung Cancer That is Unable to be
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- (no location specified)
May 16, 2023
Melanoma, Skin Cancer Trial in Tampa (Panobinostat, Ipilimumab)
Completed
- Melanoma
- Skin Cancer
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Jan 18, 2023
Recurrent Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma Trial in Buffalo (Recombinant Human Hsp110-gp100
Terminated
- Recurrent Melanoma
- +3 more
- Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine
- Laboratory Biomarker Analysis
-
Buffalo, New YorkRoswell Park Cancer Institute
Jul 20, 2022
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous
Active, not recruiting
- Clinical Stage III Cutaneous Melanoma AJCC v8
- +20 more
- Ipilimumab
- +3 more
-
Tampa, Florida
- +6 more
Jan 13, 2023
Melanoma, Unresectable Melanoma Trial in Los Angeles, Boston, New York (Sarilumab, Ipilimumab Injection, Nivolumab/Relatlimab)
Not yet recruiting
- Melanoma
- Unresectable Melanoma
- Sarilumab
- +2 more
-
Los Angeles, California
- +3 more
Aug 4, 2022
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma Trial in
Not yet recruiting
- Clinical Stage III Cutaneous Melanoma AJCC v8
- +4 more
- Rigosertib
- +4 more
-
Nashville, TennesseeVanderbilt University/Ingram Cancer Center
Feb 28, 2023
Melanoma Stage III, Melanoma Stage IV Trial in Amsterdam (T-VEC)
Recruiting
- Melanoma Stage III
- Melanoma Stage IV
-
Amsterdam, NH, NetherlandsAntoni van Leeuwenhoek ziekenhuis
Feb 11, 2022
Advanced Malignant Solid Tumor, Stage III Cutaneous Melanoma AJCC v7, Stage III Prostate Cancer AJCC v7 Trial in New Brunswick
Active, not recruiting
- Advanced Malignant Solid Neoplasm
- +9 more
- Akt Inhibitor MK2206
- Hydroxychloroquine
-
New Brunswick, New JerseyRutgers Cancer Institute of New Jersey
Jan 25, 2023